Recent reports on the impressive efficacy of adoptively transferred T cells to challenge cancer in early phase clinical trials have significantly raised the profile of T cell therapy. Concomitantly, general expectations are also raised by these reports, with the natural aspiration to deliver this therapy over a wide range of tumor indications. Chimeric antigen receptors (CARs) endow T cell populations with defined antigen specificities that function independently of the natural T cell receptor and permit targeting of T cells towards virtually any tumor. Here, we review the current clinical application of CAR-T cells and relate clinical efficacy and safety of CAR-T cell trials to parameters considered critical for CAR engineering, classified as the three T's of CAR-T cell manipulation.

Adoptive cell therapy, Cancer, Chimeric antigen receptor, Gene transfer, Immunotherapy, T cell,
Trends in Molecular Medicine
This work was funded by the European Commission 7th Framework Programme; grant id fp7/238778 - Advanced Teaching and TRaining for Adoptive Cell Therapy (ATTRACT)
Department of Medical Oncology

Gilham, D.E, Debets, J.E.M.A, Pule, M, Hawkins, R.E, & Abken, H. (2012). CAR-T cells and solid tumors: Tuning T cells to challenge an inveterate foe. Trends in Molecular Medicine (Vol. 18, pp. 377–384). doi:10.1016/j.molmed.2012.04.009